1. Home
  2. CRGX vs FAX Comparison

CRGX vs FAX Comparison

Compare CRGX & FAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CRGX
  • FAX
  • Stock Information
  • Founded
  • CRGX 2021
  • FAX 1986
  • Country
  • CRGX United States
  • FAX United States
  • Employees
  • CRGX N/A
  • FAX N/A
  • Industry
  • CRGX
  • FAX Investment Managers
  • Sector
  • CRGX
  • FAX Finance
  • Exchange
  • CRGX Nasdaq
  • FAX Nasdaq
  • Market Cap
  • CRGX 621.4M
  • FAX 629.1M
  • IPO Year
  • CRGX 2023
  • FAX N/A
  • Fundamental
  • Price
  • CRGX $12.04
  • FAX $15.32
  • Analyst Decision
  • CRGX Strong Buy
  • FAX
  • Analyst Count
  • CRGX 6
  • FAX 0
  • Target Price
  • CRGX $31.80
  • FAX N/A
  • AVG Volume (30 Days)
  • CRGX 301.4K
  • FAX 833.6K
  • Earning Date
  • CRGX 11-12-2024
  • FAX 01-01-0001
  • Dividend Yield
  • CRGX N/A
  • FAX 12.09%
  • EPS Growth
  • CRGX N/A
  • FAX N/A
  • EPS
  • CRGX N/A
  • FAX N/A
  • Revenue
  • CRGX N/A
  • FAX N/A
  • Revenue This Year
  • CRGX N/A
  • FAX N/A
  • Revenue Next Year
  • CRGX N/A
  • FAX N/A
  • P/E Ratio
  • CRGX N/A
  • FAX N/A
  • Revenue Growth
  • CRGX N/A
  • FAX N/A
  • 52 Week Low
  • CRGX $10.91
  • FAX $2.33
  • 52 Week High
  • CRGX $33.92
  • FAX $2.84
  • Technical
  • Relative Strength Index (RSI)
  • CRGX 37.21
  • FAX 51.00
  • Support Level
  • CRGX $10.91
  • FAX $14.56
  • Resistance Level
  • CRGX $15.75
  • FAX $14.95
  • Average True Range (ATR)
  • CRGX 1.19
  • FAX 0.22
  • MACD
  • CRGX -0.17
  • FAX 0.06
  • Stochastic Oscillator
  • CRGX 22.97
  • FAX 90.48

About CRGX CARGO Therapeutics Inc.

Cargo Therapeutics Inc is a clinical-stage biotechnology company positioned to advance next generation, potentially curative cell therapies for cancer patients. It programs, platform technologies, and manufacturing plan are designed to directly address the key limitations of approved cell therapies, including limited durability of effect, suboptimal safety and unreliable supply. The company's program, CRG-022, is a novel CAR T-cell product candidate designed to address resistance mechanisms by targeting CD22, an alternate tumor antigen that is expressed in a vast majority of B-cell malignancies.

About FAX abrdn Asia-Pacific Income Fund Inc.

Aberdeen Asia-pacific Income Fund Inc is a United States-based closed-end, non-diversified management investment company. Its principal investment objective is to seek current income along with capital appreciation. The fund invests in Asian debt securities, Australian debt securities, European debt securities, and others.

Share on Social Networks: